Search
Search Results
-
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
IntroductionDroxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term...
-
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report
BackgroundDroxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been...
-
Management of Neurogenic Orthostatic Hypotension in Neurodegenerative Disorders: A Collaboration Between Cardiology and Neurology
Treatment of patients with α-synucleinopathies (e.g., Parkinson disease, multiple system atrophy, diffuse Lewy body disease) may require clinicians...
-
-
Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions
Multiple system atrophy (MSA) is a sporadic, fatal, and rapidly progressive neurodegenerative disease of unknown etiology that is clinically...
-
Persistent unexplained chest pain and dyspnea in a patient with coronary artery disease: a case report
BackgroundNeurogenic orthostatic hypotension, a sustained decrease in blood pressure upon standing, is caused by autonomic nervous system failure and...
-
Treatment Updates in Postural Tachycardia Syndrome
Purpose of reviewPostural tachycardia syndrome is a common condition characterized by the presence of orthostatic intolerance in conjunction with...